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 Editorial
Anaesthetic induction with propofol: How much?  How fast? How slow? 
”What determines anesthetic induction dose? It’s the Front-End Kinetics, Doctor!”1
It has long been realised that linear dosing according to total body 
weight (TBW) results in overdosing obese patients and under-dosing 
small children. Injected drug doses calculated on a mg.kg-1 body weight 
basis work well only for patients of normal habitus. As long ago as 
1969, in a study of induction doses of thiopentone, Wulfsohn and Joshi2 
concluded that thiopentone was better administered according to 
lean body mass (LBM) than to TBW. They reasoned that endomorphic 
somatotypes required less thiopentone than mesomorphs and 
ectomorphs of the same TBW, because they had less LBM. They pointed 
out that there is a strong association between LBM, cardiac output 
and basal metabolic rate, and suggested that the LBM contained the 
“pharmacologically active mass”. Obese patients can perhaps be loosely 
regarded as ordinary individuals entrapped in a cocoon of fat into which 
hardly any injected drug is distributed. However the LBM of obese 
persons also increases as they accumulate fat, mainly due to increased 
muscle mass, as well as enlargement of other organs and blood volume. 
The dilemma is that LBM does not increase at the same rate as the 
increase in fat. Thus, although we know that they need more drug than 
normal-weight patients, how much more is often uncertain. 
In this edition of the Journal, Smith and co-workers report how they 
addressed this question with regard to propofol, regarding induction 
of anaesthesia in normal-weight, overweight and obese patients. They 
scaled the doses according to an equation based on the assumption 
that as much as 40% of an obese patient’s excess body weight is due 
to an accompanying increase in LBM.3 Besides noting the number 
of patients who lost consciousness, they recorded the processed 
electroencephalogram (EEG) whereby they could assess the maximum 
depth of hypnosis, as well as document the duration that State Entropy 
(SE) remained below a threshold of 60. Only two of the 96 subjects did 
not lose consciousness and additionally, their SE values did not dip below 
the 60 threshold. Regarding those who lost consciousness, there was a 
wide scatter of the EEG data: Lowest SE values ranged from 7 to 55 and 
the duration that SE values were less than 60 ranged from three seconds 
to 10.7 minutes. Thus some patients experienced an overshoot with 
regard to depth of hypnosis and duration of effect, while others were 
unconscious barely for long enough to permit airway management.
The time course of drug concentrations can be mathematically modelled 
using classic two- or three-compartment mammillary pharmacokinetic 
models whereby drug is injected into a central compartment from which 
it is excreted, distributed to peripheral compartments and redistributed. 
These models have been successfully implemented in target-controlled 
infusion pumps in routine use. However although these models can 
achieve and maintain desired blood and even effect-site concentrations 
with a clinically acceptable degree of accuracy, they are poor at 
predicting the fate of drugs during the first few minutes after intravenous 
injection. There are two weaknesses: firstly, the central compartment is 
regarded as a uniform, well-stirred “black box” that contains not only 
the blood circulation but also unspecified organs (Figure 1). Secondly, 
it is assumed that upon injection, drug instantaneously fills the central 
compartment. Fortunately, even though the model is wrong, it can 
successfully predict blood and brain drug concentrations when given 
by infusion. The words of the eminent statistician, George Box echo true: 
“Remember that all models are wrong; the practical question is how wrong 
do they have to be, to not be useful”.4
Obviously, drug is never instantaneously distributed into a “well-stirred” 
central compartment. Following rapid injection, a chain of physiological 
and anatomical factors, from the site of entry to the cerebral circulation, 
determine the time course of arterial concentrations and ultimately 
the effect site concentrations.5  Firstly, drug is mixed in the venous 
flow before entering the pulmonary circulation, through which it must 
undergo a first-pass before entering the systemic circulation. The lungs 
delay the passage of drugs and may even remove some.6-8  The systemic 
circulation then distributes drug to various organs (including the 
targeted organ) through which it is also subjected to a first-pass process. 
Thereafter a portion is returned to the venous flow and recirculated. 
Figure 2 illustrates how a lot more takes place within the “black box”.  







Figure 1. A typical two-compartment mammillary pharmacokinetic 
model
Figure 2. A recirculatory pharmacokinetic model for drugs injected 
rapidly into the venous circulation
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“front-end” kinetics” a term that was coined in an editorial by Krejcie 
and Avram,1 commenting on studies of chronically instrumented 
sheep by Upton and co-workers.9 The course of events is akin to the 
measurement of cardiac output by dye- or thermo-dilution, whereby 
the area under the arterial concentration-time curve is inversely related 
to the cardiac output. Various studies have indicated that cardiac output 
has a particularly important influence on blood drug concentrations.10 
As cardiac output increases, peak arterial concentrations decrease in 
response to a bolus dose and the area under the arterial concentration-
time curve decreases, leading to decreased effects on the targeted 
organ. Distribution of arterial blood flow to the brain also plays an 
important role in determining the extent of drug effect; the greater the 
cerebral blood flow, the higher the peak brain concentrations and the 
greater the effects.11  
Hybrid mathematical models that incorporate circulatory physiology 
into compartmental models (including lung first-pass kinetics and 
recirculation phenomena) have been shown to satisfactorily predict 
the early time course of propofol concentrations in the circulation and 
the brain.12 These models have been expanded to include cerebral 
blood flow and dynamics.  They are able to simulate the complex 
effects that circulatory changes exert on the pharmacokinetics and 
pharmacodynamics of propofol in sheep,9,11-14 as well as in humans.12 The 
simplest model consists of two compartments, the lungs  (Vlung), which 
receives the total cardiac output and the rest of the body (Vbody) from 
which clearance occurs.15 The mathematics associated with this model 
are complex, however they have been programmed into a spreadsheet, 
to provide a useful tool for teaching front-end kinetics (kindly supplied 
by Prof. Richard Upton15). The examples that follow, simulate the time 
courses of concentrations of an hypothetical lipid-soluble drug with 
properties similar to thiopentone or propofol. 
Example 1 
The influence of cardiac output on arterial drug concentrations. 
In Figure 3, 100 mg is administered during one minute to three identical 
“patients” whose cardiac outputs differ from low (2.5 L.min-1) to normal 
(5 L.min-1) to high (10 L.min-1). A dotted line indicates an hypothetical 
threshold for loss of consciousness. The graph illustrates the following.
Comparing the high cardiac output patient with the  normal patient:
• The onset of hypnosis is delayed slightly.
• The peak concentration is decreased.
• The duration of hypnotic effect is reduced.
The opposite occurs in the patient with the low cardiac output:
• The onset of hypnosis occurs a little earlier.
• The peak concentration is increased, implying possible haemodynamic 
effects.16
• The duration of hypnosis is greatly increased due to the drug 
concentration overshoot.
Example 2
The rate of injection influences arterial drug concentrations.
In Figure 4, 100 mg is administered at different rates to identical 
“patients” with the same “normal” cardiac output of 5 L.min-1; i.e. during 
30, 60,120 and 180 seconds. These graphs illustrate the following:
The rapid injection (20 seconds) produces:
• A short onset time
• A high peak arterial concentration that is rapidly achieved (an 
overshoot), again leading to possible haemodynamic side effects. 
• A short duration of hypnosis
A slower rate of injection (60 seconds) results in:
• A slightly longer onset time
• A lower peak arterial concentration that is achieved later
• Little difference in the duration of hypnosis
A more prolonged rate of injection (120 seconds) ensues in:
• A prolonged onset time
Figure 3. Graphs illustrating how cardiac output influences early arterial 
drug concentration profiles following rapid intravenous infusion
Simulation demonstrating the the influence of various cardiac outputs on arterial 
drug concentrations after injection of an hypothetical anaesthetic induction agent 
100 mg during one minute.
Patient parameters: Clearance = 2 L.min-1;  Volumes of distribution, Vlung = 2.5 L; 
Vbody = 15 L. 
The dotted line depicts a threshold arterial concentation at which loss of 
consciousness occurs. 
CO = cardiac output (L.min-1).
Figure 4. Graphs illustrating how varying the rate of injection influences 
arterial drug concentrations
Simulation demonstrating arterial drug concentrations resulting from injection 
of an hypothetical anaesthetic induction agent 100 mg at various rates. Patient 
parameters: CO = 5 L.min-1; Clearance 2 L.min-1;  Volumes of distribution: Vlung = 
2.5 L; Vbody = 15 L.
The dotted line depicts an hypothetical arterial concentration at which 
consciousness is lost
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• A low peak concentration that is achieved much later
• A short duration of effect
Of course a point is reached when the rate of injection (180 seconds) is 
too slow for the arterial concentrations to reach hypnotic levels. 
Example 3
Effect of increasing body size only, without increasing cardiac output or 
clearance.
Figure 5 illustrates the hypothetical situation whereby the size of 
the body compartment is doubled. The graph is self explanatory: the 
concentration-time profiles are virtually identical.
Example 4
Effect of increasing drug clearance only, without increasing cardiac output 
or the volume of distribution.
Figure 6 illustrates the hypothetical situation whereby the clearance is 
doubled. Again, the concentration-time profiles are virtually identical. 
Examples 3 and 4 illustrate that during the first minutes following 
intravenous injection, variation of body size and clearance per se do not 
exert much influence on the arterial concentration-time profile.
Example 5
Influence of both increased body size and cardiac output on arterial drug 
concentrations: application of Forbes & Welle’s dose adjustment equation.3 
The somewhat unintuitive finding in Example 3 leads to the hypothesis 
that adjusting the induction dose for obese patients should rather be 
based on the known fact that obesity is accompanied by increased 
resting cardiac outputs.17 De Simone and co-workers derived an 
allometric equation to predict cardiac output from TBW.18
Cardiac output (L.min-1)=235*TBW^0.71
Figure 7 illustrates injection of our hypothetical induction agent, 100 mg 
during one minute, to two patients, weighing 75 kg and 150 kg, each 
1.75 m tall. The obese patient is assigned an increased cardiac output 
from the normal 5 L.min-1 to 8.2 L.min-1, calculated using the above 
equation and the volume of distribution is increased from 15 L to 30 L. 
The result is as expected: the arterial drug concentration profile of the 
obese patient is generally lower and smaller. We may now investigate 
whether the dosing weight adjustment equation of Forbes & Welle3 is 
actually compensating for the obese patient’s increased resting cardiac 
output.
In the case of the obese patient:
Adjusted body mass for dosing=IBM+(0.4*(TBW-IBM))=104.5 kg
where IBM = ideal body mass which is calculated as follows:
IBM=24.2* height ^2=74.1 kg
(Assuming an ideal BMI of 24.2 kg/m2)
The standard dose to the normal weight patient was 1.3 mg.kg-1. 
Applying this dose to the adjusted body mass of 104.5 kg results in a 
dose of 141 mg to be administered to the obese patient. The resulting 
stippled plot in Figure 7 is almost identical to the drug concentration-
Figure 5. Effect of doubling the peripheral volume of distribution while 
keeping the cardiac output constant
Dose: 100 mg administered during 60 s.
Patient parameters: CO = 5 L.min-1; Clearance 2 L.min-1; Volumes of distribution: 
Vlung = 2.5 L; Vbody 15 L & 30 L
Figure 6. Effect of doubling the clearance while keeping the cardiac 
output constant
Dose: 100 mg administered during 60 s.
Patient parameters: CO = 5 L.min-1; Volumes of distribution: Vlung = 2.5 L; Vbody 
15 L; Clearance 2 L.min-1 & 4 L.min-1
Figure 7.  Application of the adjusted dosing weight equation of Forbes 
& Welle to an obese patient.
Simulation of the concentration-time courses after injecting 100 mg of the 
hypothetical induction agent during one minute into a normal-weight patient  
and into an obese patient. The stippled plot depicts the result after an adjusted 
dose of 141 mg
Normal weight patient: TBW 75 kg; Height 1.75 m; Cardiac output 5 L.min-1; 
Clearance 2 L.min-1; Vlung 2.5 L; Vbody 15 L.
Obese patient: TBW 150 kg; Height 1.75 m; Cardiac output 8.2 L.min-1; Clearance 2 
L.min-1; Vlung 2.5 L; Vbody 30 L.
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time profile of a dose of 100 mg administered to the normal-weight 
patient. We may perhaps hypothesize that the adjusted dosing mass is 
really adjusting for the increased cardiac outputs of obese patients.
Example 6
Titration of to the point of loss of consciousness:
Patients who may have low cardiac outputs and additionally, a low 
threshold concentration for loss of consciousness (e.g. hypovolaemia; 
elderly, frail patients) present a challenge to anaesthetists who 
prudently induce anaesthesia by slow intravenous injection. The 
following simulation demonstrates the dose-sparing effect of such 
an approach. Figure 8 depicts induction of such a patient by three 
different constant-rate infusions until the point of loss of consciousness. 
It is assumed for the hypothetical drug that there is a 30 second delay 
for transfer from the arterial circulation to the effect site and that the 
threshold for loss of consciousness is five concentration units. The most 
rapid infusion (100 mg.min-1) requires the highest dose and produces 
a rapid loss of consciousness at a cost of a large overshoot. The slower 
infusion rates progressively prolong the times to loss of consciousness 
with accompanying smaller doses (Table 1).
Table 1: Results of titration to effect by three different infusion rates
Infusion rate 
(mg.min-1)









100 0.65 65 19
50 0.82 41 11
25 1.22 30.5 7
It should be noted that not all obese patients have healthy hearts 
and increased cardiac outputs. Certain morbidly obese patients have 
comorbidities including obesity cardiopathy17 that predispose to 
left ventricular dysfunction as well as pulmonary hypertension and 
cardiac failure. Ill-considered application of the adjusted dosing weight 
equation of Forbes and Welle3 may result in unexpected adverse effects.
These simulations have several weaknesses. Firstly, the model does not 
predict  cerebral blood flow and effect site concentrations as has been 
done with regard to both sheep11,19-23 and humans.12 Secondly, it would 
have been useful to specifically simulate the kinetics of propofol, the 
drug that is most commonly employed for anaesthetic induction, as has 
been demonstrated by Upton and Ludbrook9,12,19-22.  Nevertheless, this 
simplified recirculatory model, simulating injection of drug somewhat 
similar to propofol, adequately demonstrates the basic principles of 
front-end kinetics that are in accordance with more sophisticated 
models. The model is also consistent with previous studies that call 
attention to the influence of cardiac output and the speed of injection 
on induction of anaesthesia,10,16,24-28
JF Coetzee 
Department of Anaesthesiology and Critical Care, Faculty of Medicine and 
Health Sciences,Stellenbosch University
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